NVG-2089 not checked

Nuvig Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Immune Thrombocytopenia (ITP)
Main trialPhase 2
“The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.”In the company’s words, NCT07095127 on ClinicalTrials.gov

Other drugs for Immune Thrombocytopenia (ITP)

All 32 drugs for Immune Thrombocytopenia (ITP)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 30 Jun 2027 Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Phase 2Terminated 1 Oct 2026 Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow NVG-2089

Following is part of Solo: you see every change to NVG-2089 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in